Genetically Modified NK Cells Enhancing Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using NK cells face limitations due to cancer cells' ability to evade immune responses, including expression of decoy TRAIL receptors and inhibitory receptors, leading to reduced cytotoxicity and increased susceptibility to normal cells, necessitating enhanced cytotoxic phenotypes and targeted therapies.
Innovation Solution
Genetically modified NK cells with knocked-out checkpoint inhibitory receptors such as CD279 (PD-1) and/or TIGIT, and enhanced TRAIL ligand expression, including mutant variants with increased affinity for death receptors, to improve cytotoxicity against cancer cells while minimizing suppression by cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhibitory receptor function is reduced on NK cells, then cytotoxicity against cancer cells is improved, but susceptibility to attack normal cells increases
Solution Approach 1:
The patent applies local quality by selectively removing specific inhibitory receptor types (checkpoint inhibitors like PD-1, TIM-3, LAG-3) while preserving other inhibitory receptors that recognize MHC class I molecules. This creates a localized modification where only certain inhibitory functions are reduced, allowing enhanced cytotoxicity against cancer cells that lack MHC class I or express MHC class I variants, while maintaining protection against normal cells through preserved MHC class I recognition pathways.
2Reliability
If TRAIL ligand expression is overexpressed on NK cells, then anti-cancer mechanism is enhanced, but cancer cells with decoy TRAIL receptors can still evade apoptosis
Solution Approach 1:
The patent employs composite materials by combining multiple killing mechanisms within the NK cell: TRAIL ligand expression is combined with perforin-granzyme cytotoxicity and FasL-mediated apoptosis. This multi-modal approach ensures that even if cancer cells express decoy TRAIL receptors, the NK cells can still eliminate them through alternative mechanisms, creating a composite anti-cancer strategy that overcomes single-pathway evasion.
3Reliability
If genetic modification is applied to remove inhibitory receptor function, then cytotoxicity is increased, but specificity for cancer cells may be reduced
Solution Approach 1:
The patent applies local quality by selectively removing specific inhibitory receptor types (checkpoint inhibitors like PD-1, TIM-3, LAG-3) while preserving other inhibitory receptors that recognize MHC class I molecules. This creates a localized modification where only certain inhibitory functions are reduced, allowing enhanced cytotoxicity against cancer cells that lack MHC class I or express MHC class I variants, while maintaining protection against normal cells through preserved MHC class I recognition pathways.
Solution Approach 2:
The patent uses MHC class I molecules as intermediaries to maintain specificity. By preserving inhibitory receptors that recognize MHC class I, the NK cells use these molecules as intermediary signals to distinguish normal cells (which express conventional MHC class I) from cancer cells (which may lack MHC class I or express variants). This intermediary mechanism ensures that genetic modifications enhance cytotoxicity without sacrificing specificity.
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to remove checkpoint inhibitory receptor expression and/or add mutant (variant) TRAIL ligand expression.